Extensive team work is in my opinion an excellent presentation of current knowledge about the new drug, actually a new group of small-molecule targeted DMARDs in rheumatology. This group of drugs is not only another excellent therapeutic option, but also the opening of a new chapter in the history of rheumatology, which is a bridge between classical DMARDs and a growing spectrum of more biological medicines. Inhibitors of Janus kinases open up possibilities both for new applications of the proposed group of drugs and for various therapeutic variants that will only be developed in everyday clinical practice, The new therapeutic option raises hopes not only for the treatment of ill adults, but also for children who may become the great beneficiaries of introducing this group of drugs - Janus kinase inhibitors.